Chordia Therapeutics (TSE:190A) General and Admin. Expense: 円0.00 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics General and Admin. Expense?

Chordia Therapeutics TSE:190A -2.53% 11 General and Admin. Expense is 円0.00 Mil as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Chordia Therapeutics's General and Admin. Expense for the six months ended in Feb. 2026 was 円0.00 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2026 was 円0.00 Mil.

Chordia Therapeutics General and Admin. Expense Related Terms

Chordia Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics General and Admin. Expense Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
General and Admin. Expense
0.00 0.00 0.00 0.00 0.00

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
General and Admin. Expense Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of 円0.00 Mil mean?
Chordia Therapeutics (TSE:190A) has a General and Admin. Expense of 円0.00 Mil as of Feb. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Chordia Therapeutics and its competitors.
Is Chordia Therapeutics' General and Admin. Expense too high?
Chordia Therapeutics' current General and Admin. Expense is 円0.00 Mil. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' General and Admin. Expense compare to VRTX and REGN?
Chordia Therapeutics' General and Admin. Expense of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current General and Admin. Expense is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current General and Admin. Expense of 円0.00 Mil. The current General and Admin. Expense is 円0.00 Mil. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current General and Admin. Expense is 円0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price